Gene Editing: Can a Single Injection Provide Lifelong Freedom from Medication?
Modern science is now advancing toward eradicating conditions like high cholesterol and heart disease from the root by directly modifying DNA.
Imagine that you do not need to take a pill every morning to keep your high cholesterol under control. Instead, receiving just a single treatment at a hospital keeps your body healthy for decades. This is not science fiction, but it is coming close to becoming a reality thanks to gene editing technology. Gene editing is a modern molecular biology method that can make extremely precise modifications to the DNA of a living organism. According to a report by ScienceDaily, this technology can become an alternative to lifelong medications not only for severe diseases, but also for common problems such as diabetes and heart disease.
Traditional medicines generally work only as long as the patient continues to take them. When the medication is stopped, its effect also diminishes. In contrast, genomic therapy works directly on the genetic material. It can introduce a healthy copy of a defective gene, block harmful biological activity, or correct a specific DNA sequence. This type of treatment is known as a 'one-and-done' treatment, meaning it is performed only once. According to experts at University of Michigan Health, this approach can revolutionize the medical world.
- Target IdentificationGuide RNA finds that specific part of the DNA where the modification is to be made.
- DNA CuttingCas9 enzyme acts as molecular scissors, cutting both strands of DNA at a precise location.
- Cellular RepairThe cell's own repair system is activated and attempts to join the cut ends.
- Gene EditingDuring repair, either the gene is inactivated or a new DNA sequence is inserted.
History of Gene Editing and the Discovery of CRISPR
The biggest name in the world of gene editing is CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats). The history of this technology is very interesting. According to Wikipedia data, in 1987 Ishino and his team first observed unusually repeating DNA sequences in bacteria. Subsequently, in 1993 Francisco Mojica studied these sequences in depth and in 2001 named them 'CRISPR'. This is naturally a part of the bacterial immune system, which protects them from virus attacks. When a virus attacks a bacterium, the bacterium stores a small fragment of that virus's DNA in its own genome, which is called a 'spacer'.
This spacer helps identify and destroy the same virus if it attacks again in the future. In this process, an enzyme, specifically a protein named Cas9 (CRISPR-associated protein 9), plays an important role. Cas9 acts like molecular scissors that can cut a specific part of the DNA. In 2020, Emmanuelle Charpentier and Jennifer Doudna were awarded the Nobel Prize in Chemistry for developing this technology. Today, this technology is being used to correct genetic defects present in human cells.
| Type | Mechanism of Action | Result |
|---|---|---|
| SDN1 | Random modification at target site | Gene is inactivated (Knock-out) |
| SDN2 | Use of small DNA fragment | Specific nucleotide change occurs |
| SDN3 | Insertion of large DNA sequence | New gene is inserted (Knock-in) |
How it Works: The Molecular-Level Process
Although the process of gene editing is extremely complex, its fundamental principle is simple. When the Cas9 protein is combined with guide RNA, it locates a precise target from among the cell's billions of DNA letters. Once the target is found, Cas9 cuts both strands of the DNA there. This cut activates the cell's own repair mechanism. According to Wikipedia, this process is called Site Directed Nucleases (SDN), which has three main types.
The first type is SDN1, which inactivates a defective gene by making a random mutation, or change, at the target. The second type is SDN2, which uses a small foreign DNA fragment from outside to correct a short DNA sequence. The third type is SDN3, which is used to insert a large new gene at a specific location in the genome. This process utilizes a natural mechanism called Homology Directed Repair (HDR). Through these methods, scientists can permanently alter disease-causing genes.
New Hope for Common Diseases
Until now, gene therapy has been used primarily for rare genetic disorders. More than 6,000 rare genetic abnormalities have been identified worldwide. This technology has achieved major success in diseases such as sickle cell disease and spinal muscular atrophy. But now researchers are turning their attention to common diseases such as high cholesterol, heart disease, obesity, and diabetes. According to a report by ScienceDaily, researchers are working on gene editing treatments that could permanently lower the levels of LDL, or 'bad' cholesterol, in the body.
ટકાવારી (%)
If this succeeds, millions of people could be freed from having to take daily medications such as statins. However, applying this technology to common diseases is a major challenge. In rare diseases, patients have no other options, so taking risks is considered justified. But safe medicines are already available for cholesterol or diabetes. Therefore, before providing permanent treatments like gene editing, it is essential that safety standards are extremely strict. Even a small mistake could have a severe impact on the health of millions of people.
Safety, Risks and Ethical Questions
The greatest risk in gene editing lies in "off-target" effects. This means that if the molecular scissors cut a segment of DNA other than the intended target, it can trigger new diseases or problems such as cancer. Furthermore, many gene therapies use viruses as vectors. Our immune system can recognize these viruses and attack them. If this happens, repeating the treatment becomes impossible. This is precisely why it is called "one-and-done," as a second chance may not be available.
Another important issue is that these modifications are permanent. In conventional medicine, if a side effect occurs, the medication can be stopped or the dosage changed. In gene editing, once a change has been made, reversing it is extremely difficult. Researchers are currently working on developing an "off-switch" to halt the effects of gene editing when necessary. At present, these treatments are performed exclusively on somatic cells—that is, ordinary body cells—so that the changes are not passed on to future generations. Germline editing, which alters reproductive cells, remains ethically controversial.
| Sequence | Evaluation Factor |
|---|---|
| 1 | Is this disease severe? |
| 2 | Are other safe treatments available? |
| 3 | Will the effect of treatment be permanent? |
| 4 | Is this treatment affordable and accessible? |
| 5 | Has long-term safety been proven? |
Cost and the Road Ahead
The biggest hurdle in this journey of gene editing is its cost. According to ScienceDaily, some currently available gene therapies cost upwards of $1,000,000 ($1,000,000). Some treatments are even more expensive than this. If this technology is to be used for common diseases, its cost must be affordable for the average person. If only wealthy individuals can access this treatment, it will widen health disparities in society. Therefore, researchers and policymakers must emphasize affordable and accessible technology.
In the future, gene editing may become as common as vaccination. Just as we receive vaccines in childhood for protection against diseases, in the future, individuals at risk of heart disease or diabetes might secure themselves with a single gene editing procedure. However, reaching that point still requires many years of clinical trials and long-term monitoring. Science is leading us toward a world where the cure for illness will not be hidden in pills, but within our own cells.
